Imaging of angiogenesis

Journal of Nuclear Cardiology

Volumn 11, Issue 5, 2004, Pages 617-633

  Sinusas, Albert J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BETA3 INTEGRIN; BIOLOGICAL MARKER; BMS 194796; CD51 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; MICROSOMAL AMINOPEPTIDASE; NITROIMIDAZOLE DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; RECOMBINANT FIBROBLAST GROWTH FACTOR; SYNDECAN 4; TECHNETIUM 99M; THALLIUM 201; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 1; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR;

ANGINA PECTORIS; ANGIOGENESIS; CELL ADHESION; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG EFFICACY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE THERAPY; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; ISOTOPE LABELING; LIMB ISCHEMIA; MOLECULAR BIOLOGY; NON INVASIVE MEASUREMENT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VIRAL GENE DELIVERY SYSTEM;

ANGIOGENESIS INDUCING AGENTS; CLINICAL TRIALS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 5044241617     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2004.07.001     Document Type: Review

References (119)

1. E.J. Battegay Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects J Mol Med 73 1995 333-346
2. N.S. Kleiman R.M. Califf Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000 American College of Cardiology J Am Coll Cardiol 36 2000 310-325
3. T.D. Henry B.H. Annex G.R McKendall et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis Circulation 107 2003 1359-1365
4. R. Lederman F. Mendelsohn R Anderson et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial Lancet 359 2002 2053-2058
5. A. Kocher M. Schuster M Szabolcs et al. Neovascularization of ischemic myocardium by human bone-marrow - Derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function Nat Med 7 2001 430-436
6. E. Tateishi-Yuyama H. Matsubara T Murohara et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial Lancet 360 2002 427-435
7. J.S. Forrester M.J. Price R.R. Makkar Stem cell repair of infarcted myocardium: an overview for clinicians Circulation 108 2003 1139-1145
8. T. Kinnaird E. Stabile M.S Burnett et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms Circulation 109 2004 1543-1549
9. C.L. Grines M.W. Watkins G Helmer et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris Circulation 105 2002 1291-1297
10. Stewart D. Late-breaking clinical trial abstracts. Circulation 2002 106 2986-a
11. S. Rajagopalan E.R. Mohler III R.J Lederman et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication Circulation 108 2003 1933-1938
12. M. Simons R.O. Bonow N.A Chronos et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary Circulation 102 2000 E73-86
13. P. Carmeliet Mechanisms of angiogenesis and arteriogenesis Nat Med 6 2000 389-395
14. F.J. Giordano Angiogenesis: mechanisms, modulation, and targeted imaging J Nucl Cardiol 6 1999 664-671
15. T.L. Haas J.A. Madri Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis Trends Cardiovasc Med 9 1999 70-77
16. N.P. Fam S. Verma M Kutryk et al. Clinician guide to angiogenesis Circulation 108 2003 2613-2618
17. J. Folkman Y. Shing Angiogenesis J Biol Chem 267 1992 10931-10934
18. P. Carmeliet Angiogenesis in health and disease Nat Med 9 2003 653-660
19. P. Brooks R. Clark D. Cheresh Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 1994 569-571
20. P. Brooks A. Montgomery M Rosenfeld et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1994 1157-1164
21. M. Schwartz M. Schaller M. Ginsberg Integrins: emerging paradigms of signal transduction Annu Rev Cell Dev Biol 11 1995 549-599
22. D. Shweiki A. Itin D Soffer et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 1992 843-845
23. E. Brogi G. Schatteman T Wu et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression J Clin Invest 97 1996 469-476
24. S. Banai M.T. Jaklitsch M Shou et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs Circulation 89 1994 2183-2189
25. J. Li L. Brown M et al. Hibberd VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis Am J Physiol 270 1996 H1803-11
26. S. Kourembanas R. Hannan D. Faller Oxygen tension regulates the expression of platelet-derived growth factor-B chain gene in human endothelial cells J Clin Invest 86 1990 670-674
27. S.H. Lee P.L. Wolf R Escudero et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction N Engl J Med 342 2000 626-633
28. G. Semenza Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1 J Clin Invest 106 2000 809-812
29. S.B. Freedman J.M. Isner Therapeutic angiogenesis for coronary artery disease Ann Intern Med 136 2002 54-71
30. S.B. Freedman J.M. Isner Therapeutic angiogenesis for ischemic cardiovascular disease J Mol Cell Cardiol 33 2001 379-393
31. F.J. Giordano P. Ping M.D McKirnan et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart Nat Med 2 1996 534-539
32. M. Hedman J. Hartikainen M Syvanne et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT) Circulation 107 2003 2677-2683
33. D. Losordo P. Vale J Symes et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia Circulation 98 1998 2800-2804
34. T. Rosengart L. Lee S Patel et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease Circulation 100 1999 468-474
35. R. Hendel T. Henry K Rocha-Singh et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect Circulation 101 2000 118-121
36. R. Laham F. Sellke E Edelman et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial Circulation 100 1999 1865-1871
37. P. Vale D. Losordo C Milliken et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia Circulation 102 2000 965-974
38. J. Udelson V. Dilsizian R Laham et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease Circulation 102 2000 1605-1610
39. M. Simons B. Annex R Laham et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial Circulation 105 2002 788-793
40. D. Losordo P. Vale R Hendel et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia Circulation 105 2002 2012-2018
41. Lake Tahoe Invitation Meeting 2002 J Nucl Cardiol 10 2003 223-256
42. O PET as a quantifiable index of lower extremity flow J Nucl Med 44 2003 915-919
43. L. Becker Conditions for vasodilator-induced coronary steal in experimental myocardial ischemia Circulation 57 1978 1103-1110
44. Arrighi J. Dione D. Condos S. et al. Adenosine Tc99cm-sestamibi SPECT underestimates ischemia compared with N-13 ammonia PET in a chronic canine model of ischemia J. Nucl Med 1999 40 6P
45. A. Fung K. Gallagher A. Buda The physiologic basis of dobutamine as compared with dipyridamole stress interventions in the assessment of critical coronary stenosis Circulation 76 1987 943-951
46. S. Lafitte H. Matsugata B Peters et al. Comparative value of dobutamine and adenosine stress in the detection of coronary stenosis with myocardial contrast echocardiography Circulation 103 2001 2724-2730
47. J. Pearlman M. Hibberd M Chuang et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis Nat Med 1 1995 1085-1089
48. J.J. Lopez R. J. Laham A Stamler et al. VEGF administration in chronic myocardial ischemia in pigs Cardiovasc Res 40 1998 272-281
49. J.D. Pearlman R.J. Laham M. Simons Coronary angiogenesis: detection in vivo with MR imaging sensitive to collateral neocirculation-preliminary study in pigs Radiology 214 2000 801-807
50. X. Yang E. Atalar D Li et al. Magnetic resonance imaging permits in vivo monitoring of catheter-based vascular gene delivery Circulation 104 2001 1588-1590
51. R. Brasch K. Li J Husband et al In vivo monitoring of tumour angiogenesis with MR imaging Acad Radiol 7 2000 812-823
52. J.D. Mills D. Fischer F.S. Villanueva Coronary collateral development during chronic ischemia: serial assessment using harmonic myocardial contrast echocardiography J Am Coll Cardiol 36 2000 618-624
53. F.S. Villanueva J.A. Abraham G.F Schreiner et al. Myocardial contrast echocardiography can be used to assess the microvascular response to vascular endothelial growth factor-121 Circulation 105 2002 759-765
54. A. Sinusas The potential for myocardial imaging with hypoxia markers Semin Nucl Med 29 1999 330-338
55. H. Kusuoka K. Hashimoto K Fukuchi et al. Kinetics of a putative hypoxic tissue marker, technetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium J Nucl Med 35 1994 1371-1376
56. C.K. Ng A.J. Sinusas B.L Zaret et al. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia Circulation 92 1995 1261-1268
57. W. Rumsey B. Patel K. Linder Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart J Nucl Med 36 1995 632-636
58. K. Fukuchi H. Kusuoka Y Watanabe et al. Ischemic and reperfused myocardium detected with technetium-99m-nitroimidazole J Nucl Med 37 1996 761-766
59. H. Weinstein C.P. Reinhardt J.A. Leppo Direct detection of regional myocardial ischemia with technetium-99m nitroimidazole in rabbits J Nucl Med 39 1998 598-607
60. 99mTc-labeled nitroimidazole (BMS-181321), after regional ischemia and reperfusion Circulation 92 1995 1246-1253
61. W.L. Rumsey B. Kuczynski B Patel et al. SPECT imaging of ischemic myocardium using a technetium-99m-nitroimidazole ligand J Nucl Med 36 1995 1445-1450
62. Rumsey W. Patel B. Kuczynski B. et al. Comparison of two novel technetium agents for imaging ischemic myocardium Circulation 1995 92 1-181
63. C. Archer B. Edwards J Kelly et al. Technetium labeled agents for imaging tissue hypoxia in vivo In: M. Nicolini G. Bandoli U. Mazzi (Eds.) Technetium and rhenium in chemistry and nuclear medicine 1995 Ditoriali Publishers Padova: SGE 535-539
64. 99mTc-HL91: Effects of low flow and hypoxia on a new ischemia-avid myocardial imaging agent Circulation 95 1997 1892-1899
65. 99mTc-HL91: "hot spot" detection of ischemic myocardium in vivo by gamma camera imaging Circulation 97 1998 2557-2566
66. G. Johnson III K.N. Nguyen Z Liu et al. Technetium 99m-HL-91: a potential new marker of myocardial viability assessed by nuclear imaging early after reperfusion J Nucl Cardiol 5 1998 285-294
67. 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors J Nucl Med 41 2000 169-176
68. L.L. Johnson L. Schofield P Mastrofrancesco et al. Technetium-99m-nitroimadazole uptake in a swine model of demand ischemia J Nucl Med 39 1998 1468-1475
69. L.L. Johnson L. Schofield T Donahay et al. Myocardial uptake of a (99m)Tc-nitroheterocycle in a swine model of occlusion and reperfusion J Nucl Med 41 2000 1237-1243
70. N. Ferrara T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4-25
71. N. Ferrara H. Gerber J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669-676
72. R. Tuder B. Flook N. Voelkel Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia Modulation of gene expression by nitric oxide J Clin Invest 95 1995 1798-1807
73. D.R. Collingridge V.A. Carroll M. Glaser E.O. Aboagye S. Osman O.C Hutchinson et al. The development of [(124)I] iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography Cancer Res 62 2002 5912-5919
74. S. Li M. Peck-Radosavljevic E. Koller F. Koller K. Kaserer A Krell et al. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumor cells: possible implication for tumor scintigraphy Int J Canc 91 2001 789-796
75. E. Lu W.R. Wagner U Schellenberger et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue Circulation 108 2003 97-103
76. S. Goldman Receptor imaging: competitive or complementary to antibody imaging Semin Nucl Med 27 1997 85-93
77. J.P. Xiong T. Stehle B Diefenbach et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 Science 294 2001 339-345
78. M. Humphries Integrin activation: the link between ligand binding and signal transduction Curr Opin Cell Biol 8 1996 632-640
79. R. Hynes Integrins: bidirectional, allosteric signaling machines Cell 110 2002 673-687
80. D. MacKenna S. Vaplon A. McCulloch Microstructural model of perimysial collagen fibers for resting myocardial mechanics during ventricular filling Am J Physiol 273 1997 H1576-86
81. E. Wilson Mechanical strain of rat vascular smooth muscle cells is sensed by specific extracellular matrix/integrin interactions J Clin Invest 96 1995 2364-2372
82. S. Shattil Function and regulation of the beta 3 integrins in hemostasis and vascular biology Thromb Haemost 74 1995 149-155
83. J. Murphy J. Bordet B Wyler et al. The vitronectin receptor (alpha v beta 3) is implicated in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells Biochem J 304 1994 537-542
84. S. Huang R. Endo G. Nemerow Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery J Virol 69 1995 2257-2263
85. M.A. Horton The alpha v beta 3 integrin "vitronectin receptor." Int J Biochem Cell Biol 29 1997 721-725
86. R. Clyman F. Mauray R. Kramer Beta 1 and beta 3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix Exp Cell Res 200 1992 272-284
87. D. Legler G. Wiedle F Ross et al. Superactivation of integrin (α)v(β)3 by low antagonist concentrations J Cell Sci 114 2001 1545-1553
88. N. Pampori T. Hato D Stupack et al. Mechanisms and consequences of affinity modulation of integrin alpha(v)beta(3) detected with a novel patch-engineered monovalent ligand J Biol Chem 274 1999 21609-21616
89. E. Tzima M. del Pozo S Shattil et al. Activation of integrins in endothelial cells by shear stress mediates Rho-dependent cytoskeletal alignment EMBO J 20 2001 4639-4647
90. D. Sipkins D. Cheresh M Kazemi et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging Nat Med 4 1998 623-626
91. R. Haubner H. Wester U Reuning et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting J Nucl Med 40 1999 1061-1071
92. R. Haubner H. Wester W Weber et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res 61 2001 1781-1785
93. R. Haubner H. Wester F Burkhart et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics J Nucl Med 42 2001 326-336
94. T.N. Harris S. Kalogeropoulos T Nguyen et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy Cancer Biother Radiopharm 18 2003 631-645
95. M.M. Sadeghi S. Krassilnikova J. Zhang A.A. Gharaei H.R. Fassaei L Esmailzadeh et al. Detection of injury-induced vascular remodeling by targeting activated vβ3 integrin in vivo Circulation 110 2004 84-90
96. D. Meoli M. Sadeghi S Krassilnikova et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction J Clin Invest 113 2004 1684-1691
97. Johnson L. Haubner R. Schofield L. et al. Radiolabeled RGD peptide to image angiogenesis in swine model of hibernating myocardium Circulation 2003 108 IV-405
98. Meoli D. Bourke B. Hu L. et al. Regional hypoxia correlates with radiolabeled targeted markers of myocardiol angiogenesis in ischemic rat model. J. Nucl. Med. 2002
99. Morrison M. Davis J. Ricketts S.-A. et al. Monitoring of tumor responce to therapy with a novel angiogenesis imaging agent Mol Imaging Biol 2003 2 272
100. H. Su X. Hu B Bourke et al. Detection of myocardial angiogenesis in chronic infarction with a novel technetium-99m labeled peptide targeted at αvβ3 integrin Circulation 108 2003 SIV-278-9
101. L. Dobrucki J. Hua B Bourke et al. Noninvasive imaging of hypoxia induced angiogenesis following hindlimb ischemia in mice [abstract] J Nucl Cardiol 11 2004 372
102. H. Leong-Poi J. Christiansen A.L Klibanov et al. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins Circulation 107 2003 455-460
103. D.B. Ellegala H. Leong-Poi J.E Carpenter et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3 Circulation 108 2003 336-341
104. M. Simons A. Horowitz Syndecan-4-mediated signalling Cell Signal 13 2001 855-862
105. A. Horowitz E. Tkachenko M. Simons Fibroblast growth factor-specific modulation of cellular response by syndecan-4 J Cell Biol 157 2002 715-725
106. J. Li L. Brown R Laham et al. Macrophage-dependent regulation of syndecan gene expression Circ Res 81 1997 785-796
107. R. Volk J.J. Schwartz J Li et al. The Role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction J Biol Chem 274 1999 24417-24424
108. R. Pasqualini E. Koivunen R Kain et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis Cancer Res 60 2000 722-727
109. S. Bhagwat J. Lahdenranta R Giordano et al. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation Blood 97 2001 652-659
110. A. Look R. Ashmun L Shapiro et al. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N J Clin Invest 83 1989 1299-1306
111. K. Penta J.A. Varner L Liaw et al. Del1 induces integrin signaling and angiogenesis by ligation of alpha vbeta 3 J Biol Chem 274 1999 11101-11109
112. S. Stromblad D. Cheresh Cell adhesion and angiogenesis Trends Cell Biol 6 1996 460-467
113. M. Friedlander P. Brooks R Shaffer et al. Definition of two angiogenic pathways by distinct alpha v integrins Science 270 1995 1500-1502
114. C. Hidai T. Zupancic K Penta et al. Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the avb3 integrin receptor Genes Dev 12 1998 21-33
115. Y. Aoka F.L. Johnson K Penta et al. The embryonic angiogenic factor del1 accelerates tumor growth by enhancing vascular formation Microvasc Res 64 2002 148-161
116. M. Nakahama T. Murakami S Kusachi et al. Expression of perlecan proteoglycan in the infarct zone of mouse myocardial infarction J Mol Cell Cardiol 32 2000 1087-1100
117. W. Edwards C. Anderson G Fields et al. Evaluation of radiolabeled type IV collagen fragments as potential tumor imaging agents Bioconjug Chem 12 2001 1057-1065
118. S. Furumoto K. Takashima K Kubota et al. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor Nucl Med Biol 30 2003 119-125
119. Q.-H. Zheng X. Fei X Liu et al. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents Nucl Med Biol 29 2002 761-770